

SAFETY DATA SHEET

1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

1.1 Product identifier

Product name CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS

Synonyms CANAURAL

1.2 Uses and uses advised against

Uses EAR DROPS • VETERINARY APPLICATIONS • VETERINARY USE

For the treatment of Otitis externa and dermatosis of bacterial origin in dogs and cats.

Uses advised against Do not use in animals with a perforated eardrum. Do not use concurrently with products known to be

Ototoxic. Do not use is animals with known hypersensitivity to the active substance(s) or to the excipient.

Persons with known hypersensitivities to any of the active substance(s) or the excipient in the product should avoid contact with the veterinary medicinal product.

1.3 Details of the supplier of the product

Supplier name DECHRA VETERINARY PRODUCTS (AUSTRALIA) PTY LTD

Address 2 Cal Close, Somersby, NSW, 2250, AUSTRALIA

Telephone 1300 015 825; (02) 4372 1661

 Fax
 (02) 4372 1668

 Email
 info.au@dechra.com

 Website
 http://www.dechra.com.au/

1.4 Emergency telephone numbers

Emergency 13 11 26 (Poisons Information Centre)

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

NOT CLASSIFIED AS HAZARDOUS ACCORDING TO SAFE WORK AUSTRALIA CRITERIA

2.2 GHS Label elements

No signal word, pictograms, hazard or precautionary statements have been allocated.

2.3 Other hazards

No information provided.

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances / Mixtures

Ingredient	CAS Number	EC Number	Content (w/w)
NYSTATIN	1400-61-9	215-749-0	2.06%
DIETHANOLAMINE FUSIDATE	16391-75-6	240-442-3	0.5%
NEOMYCIN B SULPHATE	28002-70-2	248-770-9	0.5%
PREDNISOLONE	50-24-8	200-021-7	0.25%
NON HAZARDOUS INGREDIENTS	Not Available	Not Available	Remainder

Page 1 of 6

4. FIRST AID MEASURES



SDS Date: 19 Apr 2021

PRODUCT NAME CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & **DERMATOSIS**

4.1 Description of first aid measures

If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to

stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.

If inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Inhalation

Skin If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.

Continue flushing with water until advised to stop by a Poisons Information Centre or a doctor.

For advice, contact a Poisons Information Centre on 13 11 26 (Australia Wide) or a doctor (at once). If Ingestion

swallowed, do not induce vomiting. Rinse mouth out with water and give plenty of water to drink.

First aid facilities Eve wash facilities and a hand wash basin are recommended.

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 for more detailed information on health effects and symptoms.

4.3 Immediate medical attention and special treatment needed

Treat symptomatically.

5. FIRE FIGHTING MEASURES

5.1 Extinguishing media

Use an extinguishing agent suitable for the surrounding fire.

5.2 Special hazards arising from the substance or mixture

Non flammable. May evolve carbon oxides, nitrogen oxides, chlorides and hydrocarbons when heated to decomposition.

5.3 Advice for firefighters

Treat as per requirements for surrounding fires. Evacuate area and contact emergency services. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

5.4 Hazchem code

None allocated.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS.

6.2 Environmental precautions

Prevent product from entering drains and waterways.

6.3 Methods of cleaning up

Contain spillage, then cover / absorb spill with non-combustible absorbent material (vermiculite, sand, or similar), collect and place in suitable containers for disposal.

6.4 Reference to other sections

See Sections 8 and 13 for exposure controls and disposal.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

7.2 Conditions for safe storage, including any incompatibilities

Store in a cool, dry, well marked area, removed from incompatible substances, foodstuffs and other drugs. Storage areas and containers should be clearly marked for drug holding, protected from light, freezing or physical damage and tightly sealed when not in use. Keep out of reach of children. Store below 25°C.

Page 2 of 6

7.3 Specific end uses

No information provided.



SDS Date: 19 Apr 2021

PRODUCT NAME CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA &

DERMATOSIS

8.1 Control parameters

Exposure standards

No exposure standards have been entered for this product.

Biological limits

No biological limit values have been entered for this product.

8.2 Exposure controls

Engineering controls Avoid inhalation. Use in well ventilated areas.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

PPE

Eve / Face Wear splash-proof goggles. Hands Wear PVC or rubber gloves.

Body Wear coveralls.

Where an inhalation risk exists, wear a Type A (Organic vapour) respirator. Respiratory







Page 3 of 6

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

VISCOUS YELLOW LIQUID **Appearance**

Odour SLIGHT ODOUR **Flammability** NON FLAMMABLE **NOT RELEVANT** Flash point **Boiling point NOT AVAILABLE Melting point NOT AVAILABLE Evaporation rate NOT AVAILABLE** pН **NOT AVAILABLE** Vapour density **NOT AVAILABLE** Relative density **NOT AVAILABLE** Solubility (water) **NOT AVAILABLE** Vapour pressure **NOT AVAILABLE NOT RELEVANT** Upper explosion limit **NOT RELEVANT** Lower explosion limit **NOT AVAILABLE Partition coefficient NOT AVAILABLE** Autoignition temperature **NOT AVAILABLE** Decomposition temperature **Viscosity NOT AVAILABLE Explosive properties NOT AVAILABLE** Oxidising properties **NOT AVAILABLE Odour threshold NOT AVAILABLE**

10. STABILITY AND REACTIVITY

10.1 Reactivity

Carefully review all information provided in sections 10.2 to 10.6.

10.2 Chemical stability

Stable under recommended conditions of storage.

10.3 Possibility of hazardous reactions

Polymerization is not expected to occur.

ChemAlert.

SDS Date: 19 Apr 2021

PRODUCT NAME CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS

10.4 Conditions to avoid

Avoid heat, sparks, open flames and other ignition sources.

10.5 Incompatible materials

Incompatible with oxidising agents (e.g. hypochlorites), acids (e.g. nitric acid) and alkalis (e.g. sodium hydroxide).

10.6 Hazardous decomposition products

May evolve carbon oxides, nitrogen oxides, chlorides and hydrocarbons when heated to decomposition.

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity May be harmful. This product is used in veterinary applications. Use safe work practices to avoid eye

contact, prolonged skin contact and ingestion. Refer to medical doctor/specialist for advice regarding

adverse side effects.

Information available for the ingredients:

Ingredient	Oral LD50	Dermal LD50	Inhalation LC50
NYSTATIN	8000 mg/kg (mouse)		
NEOMYCIN B SULPHATE	> 5 g/kg (mouse)		
PREDNISOLONE	1680 mg/kg (mouse)		

Skin Contact may result in irritation, redness, pain and rash.

Eye Contact may result in irritation, lacrimation, pain and redness.

Sensitisation Not classified as causing skin or respiratory sensitisation.

Mutagenicity Not classified as a mutagen.

Carcinogenicity Not classified as a carcinogen.

Reproductive Not classified as a reproductive toxin. This product contains trace amounts of Prednisolone, which may

damage the unborn child, at levels below that required for classification.

STOT - single exposure

Not classified as causing organ damage from single exposure. However, high level exposure may result in headache, nausea and respiratory tract irritation.

STOT - repeated

exposure

Not classified as causing organ damage from repeated exposure.

Aspiration Not classified as causing aspiration.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

No information provided.

12.2 Persistence and degradability

No information provided.

12.3 Bioaccumulative potential

No information provided.

12.4 Mobility in soil

No information provided.

12.5 Other adverse effects

No information provided.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste disposal Return to manufacturer/supplier where possible. For small amounts, bury in approved landfill site. Contact

Page 4 of 6

the manufacturer/supplier for additional information (if required).

Legislation Dispose of in accordance with relevant local legislation.



SDS Date: 19 Apr 2021

PRODUCT NAME

CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS

14. TRANSPORT INFORMATION

NOT CLASSIFIED AS A DANGEROUS GOOD BY THE CRITERIA OF THE ADG CODE. IMDG OR IATA

	LAND TRANSPORT (ADG)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
14.1 UN Number	None allocated.	None allocated.	None allocated.
14.2 Proper Shipping Name	None allocated.	None allocated.	None allocated.
14.3 Transport hazard class	None allocated.	None allocated.	None allocated.
14.4 Packing Group	None allocated.	None allocated.	None allocated.

14.5 Environmental hazards

Not a Marine Pollutant.

14.6 Special precautions for user

Hazchem code None allocated.

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Poison schedule Classified as a Schedule 4 (S4) Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP).

APVMA Numbers 35926/55272

Classifications Safework Australia criteria is based on the Globally Harmonised System (GHS) of Classification and

Labelling of Chemicals.

Inventory listings AUSTRALIA: AllC (Australian Inventory of Industrial Chemicals)

All components are listed on AIIC, or are exempt.

16. OTHER INFORMATION

Additional information

WORKPLACE CONTROLS AND PRACTICES: Unless a less toxic chemical can be substituted for a hazardous substance, ENGINEERING CONTROLS are the most effective way of reducing exposure. The best protection is to enclose operations and/or provide local exhaust ventilation at the site of chemical release. Isolating operations can also reduce exposure. Using respirators or protective equipment is less effective than the controls mentioned above, but is sometimes necessary.

RESPIRATORS: In general the use of respirators should be limited and engineering controls employed to avoid exposure. If respiratory equipment must be worn ensure correct respirator selection and training is undertaken. Remember that some respirators may be extremely uncomfortable when used for long periods. The use of air powered or air supplied respirators should be considered where prolonged or repeated use is necessary.

PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:

The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

HEALTH EFFECTS FROM EXPOSURE:

It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.



SDS Date: 19 Apr 2021 Revision No: 1

Page 5 of 6

PRODUCT NAME CANAURAL COMPOSITUM SUSPENSION FOR TREATMENT OF OTITIS EXTERNA & DERMATOSIS

Abbreviations ACGIH American Conference of Governmental Industrial Hygienists

CAS # Chemical Abstract Service number - used to uniquely identify chemical compounds

CNS Central Nervous System

EC No. EC No - European Community Number

EMS Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous

Goods)

GHS Globally Harmonized System

GTEPG Group Text Emergency Procedure Guide IARC International Agency for Research on Cancer

LC50 Lethal Concentration, 50% / Median Lethal Concentration

LD50 Lethal Dose, 50% / Median Lethal Dose

mg/m³ Milligrams per Cubic Metre
OEL Occupational Exposure Limit

pH relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly

alkaline).

ppm Parts Per Million

STEL Short-Term Exposure Limit

STOT-RE Specific target organ toxicity (repeated exposure)
STOT-SE Specific target organ toxicity (single exposure)

SUSMP Standard for the Uniform Scheduling of Medicines and Poisons

SWA Safe Work Australia
TLV Threshold Limit Value
TWA Time Weighted Average

Report status

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

Prepared by

Risk Management Technologies 5 Ventnor Ave, West Perth Western Australia 6005 Phone: +61 8 9322 1711 Fax: +61 8 9322 1794 Email: info@rmt.com.au Web: www.rmtglobal.com

[End of SDS]

Page 6 of 6



SDS Date: 19 Apr 2021